JP2016502526A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016502526A5 JP2016502526A5 JP2015542769A JP2015542769A JP2016502526A5 JP 2016502526 A5 JP2016502526 A5 JP 2016502526A5 JP 2015542769 A JP2015542769 A JP 2015542769A JP 2015542769 A JP2015542769 A JP 2015542769A JP 2016502526 A5 JP2016502526 A5 JP 2016502526A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- binding antibody
- composition according
- subject
- months
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261727334P | 2012-11-16 | 2012-11-16 | |
| US61/727,334 | 2012-11-16 | ||
| PCT/US2013/070042 WO2014078502A1 (en) | 2012-11-16 | 2013-11-14 | Use of il-1 beta binding antibodies for treating peripheral arterial disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016502526A JP2016502526A (ja) | 2016-01-28 |
| JP2016502526A5 true JP2016502526A5 (cg-RX-API-DMAC7.html) | 2016-12-28 |
Family
ID=49679654
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015542769A Pending JP2016502526A (ja) | 2012-11-16 | 2013-11-14 | 末梢動脈疾患を処置するためのＩＬ−１β結合抗体の使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (4) | US10000565B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2919811B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2016502526A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2013344796B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2891556A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2014078502A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20180291097A1 (en) * | 2015-06-04 | 2018-10-11 | Craig Basson | Use of il-1 beta binding antibodies to treat peripheral arterial disease |
| CA2988055A1 (en) | 2015-06-04 | 2016-12-08 | Novartis Ag | Use of il-1 beta binding antibodies to treat peripheral arterial disease |
| EP3328883A1 (en) | 2015-07-31 | 2018-06-06 | GlaxoSmithKline Intellectual Property Development Limited | Antibody variants |
| US11174466B2 (en) * | 2015-11-24 | 2021-11-16 | Commonwealth Scientific And Industrial Research Organisation | Production of viruses in cell culture |
| US20210292404A1 (en) * | 2016-07-21 | 2021-09-23 | Novartis Ag | Use of il-1beta binding antibody canakinumab for treating or allevating symptoms pulmonary sarcoidosis |
| US20180193003A1 (en) | 2016-12-07 | 2018-07-12 | Progenity Inc. | Gastrointestinal tract detection methods, devices and systems |
| WO2018112256A1 (en) | 2016-12-14 | 2018-06-21 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with an il-1 inhibitor |
| CA3075711A1 (en) * | 2017-09-13 | 2019-03-21 | Novartis Ag | Use of il-1 b binding antibodies for the treatment of alcoholic hepatitis |
| CA3113654A1 (en) * | 2018-09-20 | 2020-03-26 | Phasebio Pharmaceuticals, Inc. | Methods of reversing ticagrelor activity |
| JP7482866B2 (ja) | 2018-11-19 | 2024-05-14 | ビオラ・セラピューティクス・インコーポレイテッド | 生物学的治療薬による疾患処置方法およびデバイス |
| CN121197633A (zh) | 2019-12-13 | 2025-12-26 | 比特比德科有限责任公司 | 用于将治疗剂递送至胃肠道的可摄取装置 |
| CN112402359A (zh) * | 2020-11-04 | 2021-02-26 | 深圳前海鹰岗生物科技有限公司 | 一种抑制细胞炎症因子治疗痛风急性发作的聚合物微针及制备方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0020685D0 (en) | 2000-08-22 | 2000-10-11 | Novartis Ag | Organic compounds |
| CN103405768A (zh) | 2006-12-20 | 2013-11-27 | 爱克索马技术有限公司 | 用于治疗IL-1β相关疾病的方法 |
| EP2282754A2 (en) | 2008-03-26 | 2011-02-16 | Orthologic Corp. | Method of treating peripheral arterial disease |
| EP2297209A4 (en) | 2008-06-03 | 2012-08-01 | Abbott Lab | IMMUNOGLOBULINS WITH TWO VARIABLE DOMAINS AND USES THEREOF |
| AU2009256246B2 (en) | 2008-06-03 | 2013-07-18 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
| JP2012502059A (ja) * | 2008-09-05 | 2012-01-26 | ゾーマ テクノロジー リミテッド | ＩＬ−１β関連疾患を処置または予防するための方法 |
| EP2196476A1 (en) * | 2008-12-10 | 2010-06-16 | Novartis Ag | Antibody formulation |
| WO2010087972A2 (en) * | 2009-01-29 | 2010-08-05 | Abbott Laboratories | Il-1 binding proteins |
| KR20120061041A (ko) * | 2009-05-29 | 2012-06-12 | 조마 테크놀로지 리미티드 | ＩＬ?１β 항체 및 이의 결합 단편의 심혈관 관련 용도 |
| IN2012DN02634A (cg-RX-API-DMAC7.html) * | 2009-10-15 | 2015-09-04 | Abbvie Inc | |
| JP2013537415A (ja) * | 2010-08-03 | 2013-10-03 | アッヴィ・インコーポレイテッド | 二重可変ドメイン免疫グロブリンおよびその使用 |
| AU2012316083A1 (en) * | 2011-09-30 | 2014-04-17 | Novartis Ag | Use of IL-1 beta binding antibodies |
-
2013
- 2013-11-14 US US14/442,536 patent/US10000565B2/en active Active
- 2013-11-14 EP EP13798486.0A patent/EP2919811B1/en not_active Not-in-force
- 2013-11-14 WO PCT/US2013/070042 patent/WO2014078502A1/en not_active Ceased
- 2013-11-14 CA CA2891556A patent/CA2891556A1/en not_active Abandoned
- 2013-11-14 JP JP2015542769A patent/JP2016502526A/ja active Pending
- 2013-11-14 AU AU2013344796A patent/AU2013344796B2/en not_active Ceased
-
2018
- 2018-05-21 US US15/984,993 patent/US20180258166A1/en not_active Abandoned
-
2019
- 2019-06-21 US US16/448,341 patent/US20200148759A1/en not_active Abandoned
-
2021
- 2021-04-15 US US17/231,400 patent/US20210317202A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016502526A5 (cg-RX-API-DMAC7.html) | ||
| Wiegand et al. | Treatment of lymphatic malformations with the mTOR inhibitor sirolimus: a systematic review | |
| KR102446673B1 (ko) | 암 치료를 위한 약물의 제조에 있어서 항-pd-1 항체 및 vegfr 억제제의 조합의 용도 | |
| Accardi et al. | Mechanism of action of bortezomib and the new proteasome inhibitors on myeloma cells and the bone microenvironment: impact on myeloma‐induced alterations of bone remodeling | |
| ES2644022T3 (es) | Combinación de un agonista de DR5 y un antagonista de anti-PD-1 y métodos de uso | |
| RU2017108173A (ru) | Комбинированная терапия на основе антител, активирующих человеческий cd40, и антител к человеческому pd-l1 | |
| JP5417653B2 (ja) | 抗−４−１ｂｂ抗体及び化学抗癌剤を含む癌疾患の予防及び治療用調合薬学的組成物 | |
| JP2015187125A5 (cg-RX-API-DMAC7.html) | ||
| JP2015530867A5 (cg-RX-API-DMAC7.html) | ||
| JP2017528427A5 (cg-RX-API-DMAC7.html) | ||
| JP2017537105A5 (cg-RX-API-DMAC7.html) | ||
| KR20180018695A (ko) | 항암제 | |
| JP2023071715A (ja) | アテローム動脈硬化性心血管疾患を含むアテローム性動脈硬化症の併用療法 | |
| JP2013506684A5 (cg-RX-API-DMAC7.html) | ||
| JP2016537380A5 (cg-RX-API-DMAC7.html) | ||
| KR20240090993A (ko) | 류마티스성 관절염의 치료에서 또는 진통제로서 사용하기 위한 gm-csf 중화 항체 | |
| RU2011150619A (ru) | Комбинация ингибитора фосфоинозитид-3-киназы и противодиабетического соединения | |
| Frappaz et al. | Phase 1 study of dalotuzumab monotherapy and ridaforolimus–dalotuzumab combination therapy in paediatric patients with advanced solid tumours | |
| RU2013108390A (ru) | Фармацевтическая композиция для предотвращения периоперационной артериальной гипотензии у человека | |
| Topal et al. | Scleroderma therapy: clinical overview of current trends and future perspective | |
| JP2019533715A5 (cg-RX-API-DMAC7.html) | ||
| JP2018516931A5 (cg-RX-API-DMAC7.html) | ||
| RU2018114457A (ru) | Лечение syd985 пациентов с t-dm1 рефрактерным раком | |
| CN112955148B (zh) | Cdk4/6抑制剂联合免疫治疗在制备治疗淋巴瘤的药物中的用途 | |
| US20240173403A1 (en) | Combination of AXL Antibodies and ACE Inhibitors in the Treatment of Fibrosis |